Pre-Test Atypical Antipsychotics for Adjunctive Treatment of MDD: Advancing the Standard of Care Pre-Test The probability of achieving remission with 1st line therapy is approximately _____, and declines with each subsequent line of therapy 17% 27% 37% 47% Unsure Which of the following scenarios favors treatment augmentation vs treatment switching in a patient with inadequate response to antidepressant monotherapy? There is a less than 25% improvement to the first antidepressant There is more time to wait for a response (less severe, less functional impairment) There are poorly tolerated side effects to the first antidepressant There are specific residual symptoms or side effects to the original antidepressant that can be targeted Unsure Which of the following atypical antipsychotics approved as adjunctive therapy to antidepressants in MDD is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist? Aripiprazole Brexpiprazole Cariprazine Quetiapine Unsure Which of the following is the most common AE associated with cariprazine (7.6% overall incidence), which can be minimized with conservative dosing and titration strategies? Akathisia Sedation Weight gain Sleep disturbances Unsure How confident are you in your ability to tailor appropriate adjunctive treatment for patients with MDD and an inadequate/partial response to antidepressant monotherapy? Very confident Confident Somewhat confident Not very confident Not at all confident
